BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18308439)

  • 1. Exploring emerging technologies using metaphors--a study of orphan drugs and pharmacogenomics.
    Boon W; Moors E
    Soc Sci Med; 2008 May; 66(9):1915-27. PubMed ID: 18308439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethical, social and legal implications of pharmacogenomics: a critical review.
    Moldrup C
    Community Genet; 2001; 4(4):204-14. PubMed ID: 12751484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach.
    Mandry T
    Food Drug Law J; 2004; 59(4):519-35. PubMed ID: 15875348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pipeline and the porcupine: alternate metaphors of the physician-industry relationship.
    Mather C
    Soc Sci Med; 2005 Mar; 60(6):1323-34. PubMed ID: 15626527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global pharmacogenomics: where is the research taking us?
    Olivier C; Williams-Jones B
    Glob Public Health; 2014; 9(3):312-24. PubMed ID: 24580118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.
    Grabowski HG; Moe JL
    Cancer Prev Res (Phila); 2008 Jul; 1(2):84-90. PubMed ID: 19138940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethical considerations in orphan drug approval and use.
    Kesselheim AS
    Clin Pharmacol Ther; 2012 Aug; 92(2):153-5. PubMed ID: 22814660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethical and legal implications of pharmacogenomics.
    Rothstein MA; Epps PG
    Nat Rev Genet; 2001 Mar; 2(3):228-31. PubMed ID: 11256075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized medicine and rescuing "unsafe" drugs with pharmacogenomics: a regulatory perspective.
    Avery M
    Food Drug Law J; 2010; 65(1):37-65, i-ii. PubMed ID: 24475534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two decades of orphan product development.
    Haffner ME; Whitley J; Moses M
    Nat Rev Drug Discov; 2002 Oct; 1(10):821-5. PubMed ID: 12360259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The roles of patents and research and development incentives in biopharmaceutical innovation.
    Grabowski HG; DiMasi JA; Long G
    Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Race and ethnicity in the era of emerging pharmacogenomics.
    Harty L; Johnson K; Power A
    J Clin Pharmacol; 2006 Apr; 46(4):405-7. PubMed ID: 16554447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of pharmacogenomics for drug development and clinical practice.
    Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
    Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics and the challenge of health disparities.
    Lee SS
    Public Health Genomics; 2009; 12(3):170-9. PubMed ID: 19204420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the economic challenges posed by orphan drugs.
    Drummond MF; Wilson DA; Kanavos P; Ubel P; Rovira J
    Int J Technol Assess Health Care; 2007; 23(1):36-42. PubMed ID: 17234015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis to guide orphan drug development.
    Lesko LJ
    Clin Pharmacol Ther; 2012 Aug; 92(2):258-61. PubMed ID: 22739138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base.
    Thorn CF; Klein TE; Altman RB
    Methods Mol Biol; 2005; 311():179-91. PubMed ID: 16100408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orphan drug development across Europe: bottlenecks and opportunities.
    Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
    Drug Discov Today; 2008 Aug; 13(15-16):670-6. PubMed ID: 18583178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.